Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | NCK1 | P16333 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585180 | 0.95 | CYP2A6 (0.62) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL13152961 | 0.95 | CYP2A6 (0.62) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL4322069 | 0.92 | CYP2A6 (0.70) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL19660697 | 0.91 | CYP2A6 (0.56) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL25625349 | 0.88 | CYP2A6 (0.52) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL29353067 | 0.83 | CYP2A6 (0.77) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL29389285 | 0.83 | CYP1A2 (1.00) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL192166 | 0.83 | CYP2A6 (0.77) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL308248 | 0.83 | CYP1A2 (1.00) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E | |
| SCHEMBL18891725 | 0.81 | CYP2A6 (0.56) | CYP2A6CYP1A2TDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10195018-A | — | — | None | — | — | JP | disclosed |
| WO-2024257966-A1 | HIGH-REFRACTIVE-INDEX ORGANIC MATERIAL AND LIGHT-EMITTING DEVICE COMPRISING SAME | 비피시 주식회사 | 2024-12-19 | — | — | WO | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-110571340-B | Organic electroluminescent device and electronic apparatus | 陕西莱特光电材料股份有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-110534658-B | Organic electroluminescent device and electronic apparatus | 陕西莱特光电材料股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| WO-2020063760-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-04-02 | — | — | WO | disclosed |
| CN-110571340-A | Organic electroluminescent device and electronic apparatus | 陕西莱特光电材料股份有限公司 | 2019-12-13 | — | — | CN | disclosed |
| WO-2019196714-A1 | N-SUBSTITUTED ACRYLAMIDE DERIVATIVE AS DHODH INHIBITOR, AND PREPARATION AND USE THEREOF | 华东理工大学 | 2019-10-17 | — | — | WO | disclosed |
| EP-3242872-B1 | (PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER | GENENTECH INC (US) | 2019-07-03 | — | — | EP | disclosed |
| WO-2004041776-A2 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-21 | — | — | WO | disclosed |
| JP-2004091428-A | METHOD FOR PRODUCING 6-BROMO-2-NAPHTHALENECARBOXYLIC ACID | SUMIKIN AIR WATER CHEMICAL INC | 2004-03-25 | — | — | JP | disclosed |
| JP-2004083455-A | METHOD FOR MANUFACTURING 6-BROMO-2-METHYLNAPHTHALENE | SUMIKIN AIR WATER CHEMICAL INC | 2004-03-18 | — | — | JP | disclosed |
| US-5955487-A | TREATING HIGH BLOOD PRESSURE, CARDIAC INSUFFICIENCY, GLAUCOMA | CIBA-GEIGY CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| JP-H10195018-A | PRODUCTION OF METHYL 6-BROMO-2-NAPHTHALENECARBOXYLATE | SUMIKIN CHEM CO LTD | 1998-07-28 | — | — | JP | disclosed |
| EP-0528762-B1 | N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| US-5620998-A | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0528762-A1 | N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists | CIBA-GEIGY AG (CH) | 1993-02-24 | — | — | EP | disclosed |
| US-4581380-A | TREATMENT OF SKIN DISORDERS;ANTIINFLAMMATORY AGENTS | Groupement Economique dite: Centre National de Recherches Dermatologiques C.I.R.D. (FR) | 1986-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | CYP2A6 2567/4885CYP1A2 4624/4885TDP1 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.